Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec 19;14(1):136.
doi: 10.1186/s13000-019-0920-3.

MicroRNA-937 is overexpressed and predicts poor prognosis in patients with colon cancer

Huiya Liu  1 , Lin Ma  2 , Ling Wang  3 , Yizuo Yang  4
Affiliations

MicroRNA-937 is overexpressed and predicts poor prognosis in patients with colon cancer

Huiya Liu et al. Diagn Pathol. .

Abstract

Background: Colon cancer is a heterogeneous tumor and a leading cause of cancer-related mortality. MicroRNA (miRNA) has been proposed as the biomarker in cancers. The aim of this study was to investigate the clinical significance and potential functional role of miR-937 in colon cancer.

Methods: In the present study, reverse transcription-quantitative polymerase chain reaction (qRT-PCR) was conducted to examine the expression levels of miR-937 in colon cancer tissues and cell lines. Kaplan-Meier curve and Cox regression analyses were used to determine the prognostic impact of miR-937 on survival. Cell Counting Kit-8 and Transwell assays were performed to examine cell proliferation, migration, and invasion, respectively.

Results: miR-937 was significantly upregulated in colon cancer tissues and cell lines. Clinical analysis results showed that miR-937 expression was associated with lymph node metastasis and TNM stage. Patients with high miR-937 expression predicted a shorter overall survival rate. Functionally, overexpression of miR-937 promoted cell proliferation, migration, and invasion, while inhibition of miR-937 inhibited these cellular behaviors in vitro.

Conclusions: These results suggested that miR-937 may act as a prognostic biomarker and a potential target for therapeutic strategy, as well as promote proliferation, migration, and invasion of colon cancer.

Keywords: Colon cancer; Invasion; Migration; Prognosis; Proliferation; miR-937.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
The miR-937 expression is detected in colon cancer tissues and cell lines via qRT-PCR analysis. a. miR-937 expression is increased in colon cancer tissues compared with adjacent normal tissues. b. miR-937 expression is upregulated in colon cancer cells (LoVo, SW620, CW-2, HCT116) compared with a normal colonic epithelial cell line (NCM460). **P < 0.01, ***P < 0.001
Fig. 2
Fig. 2
Kaplan-Meier analysis showed that colon cancer patients with high miR-937 expression had shorter overall survival rate. The log-rank test was applied, P = 0.037
Fig. 3
Fig. 3
Overexpression and downregulation of miR-937 promotes and inhibits the proliferation of colon cancer cells (LoVo and SW620), respectively, compared with untreated cells. a. The relative expression level of miR-937 was significantly increased by miR-937 mimic, while decreased by miR-937 inhibitor in LoVo and SW620 cells, compared with that in the untreated cell. b. Cell proliferation was detected by CCK-8 assay. *P < 0.05, **P < 0.01, ***P < 0.001
Fig. 4
Fig. 4
Overexpression of miR-937 promotes the migratory and invasive capabilities, while the downregulation of miR-937 inhibits the migratory and invasive capabilities of colon cancer cells (LoVo and SW620), compared with untreated cells. a. Representative images of Transwell migration assay (magnification × 200). b. Transwell migration assay was applied to investigate migration ability. c. Representative images of Transwell invasion assay (magnification × 200). d. Transwell invasion assay was applied to investigate invasion ability. **P < 0.01, ***P < 0.001
See this image and copyright information in PMC

References

    1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi: 10.3322/caac.20107. - DOI - PubMed
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30. doi: 10.3322/caac.21332. - DOI - PubMed
    1. Svensson T, Yamaji T, Budhathoki S, Hidaka A, Iwasaki M, Sawada N, et al. Alcohol consumption, genetic variants in the alcohol- and folate metabolic pathways and colorectal cancer risk: the JPHC study. Sci Rep. 2016;6:36607. doi: 10.1038/srep36607. - DOI - PMC - PubMed
    1. Klaver CEL, Wisselink DD, Punt CJA, Snaebjornsson P, Crezee J, Aalbers AGJ, et al. Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial. Lancet Gastroenterol Hepatol. 2019;4(10):761–770. doi: 10.1016/S2468-1253(19)30239-0. - DOI - PubMed
    1. Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Niksic M, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023–1075. doi: 10.1016/S0140-6736(17)33326-3. - DOI - PMC - PubMed

LinkOut - more resources